6 terminated. 6 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Ichthyosis: new trials by email Literature Review of Ichthyosis trials Research Report on Ichthyosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis Imsidolimab, placebo - Ichthyosis | Phase 2 | Terminated | Vanda Pharmaceuticals | 5 | 2021-01-25 | 2025-09-16 |
| A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | University Hospital, Toulouse | 10 | 2020-07-23 | 2026-09-21 |
| A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle - Lamellar Ichthyosis | Phase 2 | Terminated | Mayne Pharma International Pty Ltd | 65 | 2019-05-01 | 2023-08-14 |
| Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS Doxorubicin, Trabectedin - Sarcoma | Phase 2 | Terminated | Grupo Espanol de Investigacion en Sarcomas | 115 | 2009-11-01 | 2015-10-27 |
Netherton Syndrome (3) · Ichthyosis, Lamellar (1) · Ichthyosis, X-Linked (1) · Sarcoma (1)
Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Infant, Newborn, Diseases (6) · Keratosis (6) · Skin Abnormalities (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Genetic Diseases, Inborn (5) · Skin Diseases, Genetic (5) · Ichthyosiform Erythroderma, Congenital (4) · Abnormalities, Multiple (3) · Genetic Diseases, X-Linked (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1)
Doxorubicin (1) · Injections (1) · Trabectedin (1) · spesolimab (1) · trifarotene (1)
Boehringer Ingelheim (1) · Daiichi Sankyo (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Mayne Pharma International Pty Ltd (1) · University Hospital, Toulouse (1) · Vanda Pharmaceuticals (1)
France (4) · United States (3) · Australia (2) · Germany (2) · Israel (2) · Spain (2) · United Kingdom (2) · Bulgaria (1) · Canada (1) · China (1) · Italy (1) · Japan (1) · Malaysia (1) · Netherlands (1) · Portugal (1)
Andres Poveda, Ph.M. (1) · Javier Martin Broto, PhM (1) · Keith A. Choate, MD (1)
2008 (1)